Glucosyl hesperidin-containing composition and application thereof

Abstract

The embodiment of the invention provides a glucosyl hesperidin-containing composition and application. The glucosyl hesperidin-containing composition can be used for reducing the expression level of AGER in skin cells. The composition containing the glucosyl hesperidin is prepared from raspberry ketone glucoside, the glucosyl hesperidin and an edelweiss extract.

Description

Technical Field

[0001] The present invention relates to the technical field of glucosyl hesperidin, and specifically relates to a composition containing glucosyl hesperidin and its uses. Background Art

[0002] Glycation (i.e., glycosylation) related to aging is the binding of sugars and proteins, which changes the spatial configuration and molecular structure of proteins, resulting in the loss of their physiological activity. Therefore, the glycation process is a process of destroying proteins.

[0003] Since there are various proteins in the skin that play a role in maintaining skin elasticity or keeping the skin in good appearance, after these proteins are glycated, various subsequent skin problems will occur, including skin wrinkles, skin spots, and loss of skin luster.

[0004] Advanced glycation end products (AGEs) are irreversible cross-linked compounds formed by the non-enzymatic reaction of proteins or lipids with sugars, and accumulate in the human body with age or long-term hyperglycemia (such as diabetes). AGEs can further promote the glycation reaction by activating inflammation and oxidative stress through binding to AGER proteins. That is, AGER protein is a major receptor for AGEs, and reducing the production of AGER protein may be beneficial for anti-glycation (also known as anti-aging).

[0005] Glucosyl hesperidin is a substance that can be used in skin care. Therefore, if glucosyl hesperidin can be used to reduce the expression level of AGER, it may be beneficial for providing a better way of anti-glycation for the skin. However, there is currently no research on using glucosyl hesperidin to reduce the expression level of AGER, so this remains an issue to be solved. Summary of the Invention

[0006] One objective of the embodiments of the present application is to solve at least one of the above-mentioned problems in the background and provide corresponding beneficial effects.

[0007] Another objective of the embodiments of the present application is to provide a composition containing glucosyl hesperidin and its uses, which can be used to reduce the expression level of AGER in skin cells.

[0008] The embodiments of the present application mainly achieve the above objectives through the following technical solutions.

[0009] In the first aspect, the embodiments of the present application provide a composition containing glucosyl hesperidin, including:

[0010] Rubusoside, glucosyl hesperidin, and Leontopodium alpinum extract.

[0011] In some technical solutions, the mass ratio of raspberry ketone, glucosyl hesperidin and edelweiss extract is (250 - 350):(50 - 100):(0.75 - 15).

[0012] In some technical solutions, the preparation method of the edelweiss extract includes:

[0013] Dry and crush the edelweiss to obtain an edelweiss crush;

[0014] Mix the edelweiss crush with an ethanol aqueous solution to obtain a mixed solution;

[0015] Reflux and extract the mixed solution and then filter it, and concentrate the filtrate under reduced pressure to obtain the edelweiss extract.

[0016] In yet another aspect, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of a skin care product.

[0017] In some technical solutions, raspberry ketone, glucosyl hesperidin and edelweiss extract are used to synergistically promote the expression of DDOST in skin cells.

[0018] In some technical solutions, raspberry ketone, glucosyl hesperidin and edelweiss extract are used to synergistically inhibit the expression of AGER in skin cells.

[0019] In some technical solutions, raspberry ketone, glucosyl hesperidin and edelweiss extract are used to synergistically inhibit the expression of CD-36 in skin cells.

[0020] In yet another aspect, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of a DDOST expression promoter.

[0021] In yet another aspect, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of an AGER expression inhibitor.

[0022] In yet another aspect, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of a CD-36 expression inhibitor.

[0023] In yet another aspect, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of an anti-aging preparation.

[0024] In yet another aspect, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of an anti-glycation preparation.

[0025] In another aspect, the embodiments of the present application also provide the use of raspberry glycoside, glucosyl hesperidin and edelweiss extract in the preparation of anti-aging preparations.

[0026] In another aspect, the embodiments of the present application also provide the use of raspberry glycoside, glucosyl hesperidin and edelweiss extract in the preparation of anti-glycation preparations.

[0027] In another aspect, the embodiments of the present application also provide the use of raspberry glycoside, glucosyl hesperidin and edelweiss extract in the preparation of DDOST expression promoters.

[0028] In another aspect, the embodiments of the present application also provide the use of raspberry glycoside, glucosyl hesperidin and edelweiss extract in the preparation of AGER expression inhibitors.

[0029] In another aspect, the embodiments of the present application also provide the use of raspberry glycoside, glucosyl hesperidin and edelweiss extract in the preparation of CD-36 expression inhibitors.

[0030] In another aspect, the embodiments of the present application also provide a skin care product, comprising:

[0031] Raspberry glycoside, glucosyl hesperidin and edelweiss extract.

[0032] In some technical solutions, in the skin care product, the mass ratio of raspberry glycoside, glucosyl hesperidin and edelweiss extract is (250-350):(50-100):(0.75-15).

[0033] The beneficial effects of the embodiments of the present invention include:

[0034] 1. In some embodiments, the composition provided by the embodiments of the present application, through the synergistic effect of raspberry glycoside, glucosyl hesperidin and edelweiss extract, can be used to reduce the expression level of AGER in skin cells, thereby being able to solve the problems in the background.

[0035] 2. AGEs, the inflammation and oxidative stress activated by binding to AGER protein will further promote the glycation reaction. The composition of the embodiments of the present application, through the action of raspberry glycoside, glucosyl hesperidin and edelweiss extract, can inhibit the generation of AGER protein, and thus can inhibit further glycation reactions and indirectly reduce the accumulation of this positive feedback-driven AGEs.

[0036] 3. The AGER protein is the main receptor of AGEs. After their binding, multiple pro-aging pathways are activated. For example, the activation of signaling pathways such as the NF-κB signal promotes inflammation, oxidative stress, and cell damage, leading to DNA and mitochondrial damage and accelerating cell aging. However, the composition provided in the embodiments of the present application can reduce the expression level of AGER in skin cells, thereby reducing the generation of AGER protein, decreasing the binding of AGEs to AGER protein, and achieving the effects of anti-inflammation, anti-oxidative stress, anti-cell damage, and anti-cell aging in certain embodiments.

[0037] 4. In some embodiments, the composition provided in the embodiments of the present application, through the combination of raspberry ketone, glucosyl hesperidin, and edelweiss extract, can produce a synergistic effect, thereby achieving the effect of reducing the expression level of the CD-36 gene.

[0038] 5. The CD-36 (Cluster of Differentiation 36) protein is a transmembrane glycoprotein belonging to the scavenger receptor B family and is widely involved in processes such as fatty acid transport, inflammation regulation, apoptosis, and lipid metabolism. The over-activation of the CD-36 protein is closely related to various aging-related diseases (such as atherosclerosis, insulin resistance, and neurodegenerative diseases). Inhibiting the production of the CD-36 protein can delay the aging process through mechanisms such as reducing lipotoxicity, inflammation, and oxidative stress. Therefore, it can be understood that the composition containing raspberry ketone, glucosyl hesperidin, and edelweiss extract provided in the embodiments of the present application can be used to delay the aging process by reducing the expression level of CD-36.

[0039] 6. In some embodiments, the composition provided in the embodiments of the present application, through the combination of raspberry ketone, glucosyl hesperidin, and edelweiss extract, can produce a synergistic effect and can also increase the expression level of the DDOST gene. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 It is a schematic diagram of the cell survival rate of administration experimental groups 1-5 and the control group in Experimental Example 1 of the present application;

[0041] Figure 2 It is a schematic diagram of the cell survival rate of administration experimental groups 6-10 and the control group in Experimental Example 1 of the present application;

[0042] Figure 3 It is a schematic diagram of the cell survival rate of administration experimental groups 11-15 and the control group in Experimental Example 1 of the present application;

[0043] Figure 4It is a schematic diagram of the relative mRNA expression levels of the AGER gene in the Control group, MGO group, sample 2-1 experimental group, sample 2-2 experimental group, sample 2-3 experimental group, and sample 2-4 experimental group in Experimental Example 2 of this application;

[0044] Figure 5 It is a schematic diagram of the relative mRNA expression levels of the AGER gene in the Control group, MGO group, sample 2-5 experimental group, sample 2-6 experimental group, sample 2-7 experimental group, and sample 2-8 experimental group in Experimental Example 2 of this application;

[0045] Figure 6 It is a schematic diagram of the relative mRNA expression levels of the CD-36 gene in the Control group, MGO group, sample 2-1 experimental group, sample 2-2 experimental group, sample 2-3 experimental group, and sample 2-4 experimental group in Experimental Example 2 of this application;

[0046] Figure 7 It is a schematic diagram of the relative mRNA expression levels of the CD-36 gene in the Control group, MGO group, sample 2-5 experimental group, sample 2-6 experimental group, sample 2-7 experimental group, and sample 2-8 experimental group in Experimental Example 2 of this application;

[0047] Figure 8 It is a schematic diagram of the relative mRNA expression levels of the DDOST gene in the Control group, MGO group, sample 2-1 experimental group, sample 2-2 experimental group, sample 2-3 experimental group, and sample 2-4 experimental group in Experimental Example 2 of this application;

[0048] Figure 9 It is a schematic diagram of the relative mRNA expression levels of the DDOST gene in the Control group, MGO group, sample 2-5 experimental group, sample 2-6 experimental group, sample 2-7 experimental group, and sample 2-8 experimental group in Experimental Example 2 of this application. Detailed implementation manners

[0049] The following further elaborates on the present invention with reference to the accompanying drawings, so that those skilled in the art can implement it based on the text of the specification.

[0050] The terms "first", "second", etc. in the embodiments of this application are only used for descriptive purposes and cannot be construed as indicating or implying relative importance or implicitly specifying the quantity of the indicated technical features. Thus, features defined with "first", "second", etc. may explicitly or implicitly include at least one such feature.

[0051] Furthermore, the terms "comprising", "including", and any variations thereof, are intended to cover non-exclusive inclusion. For example, a process, method, system, product, or apparatus that comprises a series of steps or elements is not limited to the listed steps or elements, but may optionally further include steps or elements not listed, or may optionally further include other steps or elements inherent to these processes, methods, products, or apparatuses.

[0052] The term "raspberry ketone" refers to: 4-[4-(beta-D-Glucopyranosyloxy)phenyl]-2-butanone, with a relative molecular mass of 326.34.

[0053] The term "glucosyl hesperidin" refers to: alpha-Glucosyl Hesperidin, with a relative molecular mass of 772.71.

[0054] The term "edelweiss" refers to the plant with the scientific name Leontopodium alpinum Colm. ex Cass.

[0055] The term "skin" includes the skin on the face, scalp, neck, chest, abdomen, back, arms, armpits, hands, and legs.

[0056] The term "AGER gene" refers to Advanced Glycation End-products Receptor, abbreviated as AGER.

[0057] The term "CD-36 gene" refers to Cluster of Differentiation 36, abbreviated as CD36, and its Chinese name is leukocyte differentiation antigen 36.

[0058] The term "DDOST gene" refers to

[0059] Dolichyl-Diphosphooligosaccharide-Protein Glycosyltransferase, abbreviated as DDOST.

[0060] The term "FBS" is an abbreviation for fetal bovine serum, referring to fetal bovine serum.

[0061] The term "penicillin / streptomycin solution" refers to a solution containing penicillin and streptomycin, where the concentrations of penicillin and streptomycin are 10,000 enzyme activity units per milliliter (U / mL) respectively.

[0062] The term "DMEM medium" is an abbreviation for Dulbecco's Modified Eagle Medium, referring to Dulbecco's modified Eagle medium.

[0063] The term "DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin solution" refers to a DMEM medium solution added with FBS and a penicillin / streptomycin mixed solution. In the DMEM medium solution, the volume fraction of FBS is 10%, and the volume fraction of the penicillin / streptomycin solution is 1%. That is, every 100 milliliters of the DMEM medium solution contains 10 milliliters of FBS and 1 milliliter of the penicillin / streptomycin mixed solution; the preparation method is as follows: mix FBS, the penicillin / streptomycin solution and the DMEM medium to obtain the DMEM medium solution.

[0064] The term "CCK8 working solution" refers to the Cell Counting Kit-8 reagent.

[0065] The term "MGO" refers to methylglyoxal.

[0066] The term "MGO solution" refers to a solution obtained by mixing 100 microliters of the DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin solution with MGO (methylglyoxal) so that the final concentration of MGO is 500 micromoles per liter (μmol / L).

[0067] The term "OD value" refers to the optical density value.

[0068] The term "RNA" refers to ribonucleic acid.

[0069] The term "mRNA" refers to messenger ribonucleic acid.

[0070] The term "RT-PCR" refers to reverse transcription polymerase chain reaction.

[0071] The term "Q-PCR" refers to quantitative polymerase chain reaction.

[0072] Unless otherwise specified, the numerical ranges in this article include the numbers themselves.

[0073] In addition to the above, it should still be emphasized that when "embodiment" is mentioned in this article, it means that the specific features, structures or characteristics described in combination with the embodiment can be included in at least one embodiment of this application. The appearance of this phrase in various positions in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment mutually exclusive with other embodiments. Those skilled in the art explicitly and implicitly understand that the embodiments described herein can be combined with other embodiments.

[0074] <Composition>

[0075] In the first aspect, an embodiment of the present application provides a composition, comprising:

[0076] raspberry glycoside, glucosyl hesperidin and edelweiss extract.

[0077] The composition provided by the embodiment of the present application can be used to reduce the gene expression level of AGER through the synergistic effect of raspberry glycoside, glucosyl hesperidin and edelweiss extract, and thus can be used to solve the problems in the background.

[0078] In addition, the composition provided by the embodiment of the present application can also produce the following technical effects:

[0079] 1. The composition of the embodiment of the present application can produce a synergistic effect through the combination of raspberry glycoside, glucosyl hesperidin and edelweiss extract, and thus can achieve the effect of reducing the expression level of the CD-36 gene.

[0080] 2. The composition of the embodiment of the present application can synergistically achieve the effect of increasing the expression level of the DDOST gene through the combination of raspberry glycoside, glucosyl hesperidin and edelweiss extract.

[0081] In addition, the inflammation and oxidative stress activated by AGEs binding to the AGER protein will further promote the glycosylation reaction. The composition provided by the embodiment of the present application can reduce the generation of advanced glycation end products (AGEs) by reducing the gene expression level of AGER in skin cells, thereby reducing the production of AGER protein and the binding of AGEs to the AGER protein.

[0082] In some embodiments, the CD-36 protein can bind long-chain fatty acids, oxidized low-density lipoprotein (oxLDL), phospholipids, etc., and participate in lipid metabolism, atherosclerosis, inflammation and immune responses, and is closely related to metabolic diseases (such as obesity, diabetes) and cardiovascular diseases. Therefore, it can be understood that the composition containing raspberry glycoside, glucosyl hesperidin and edelweiss extract provided by the embodiment of the present application can be used for the treatment of lipid metabolism, atherosclerosis, inflammation and immune responses, and metabolic diseases (such as obesity, diabetes) and cardiovascular diseases by reducing the expression level of CD-36.

[0083] In some embodiments, the AGER protein can bind to a variety of ligands (such as AGEs, S100 protein, HMGB1, amyloid-β, etc.), promote inflammation, oxidative stress and cell damage by activating signaling pathways such as NF-κB, and play a key role in diabetic complications, atherosclerosis, cancer and neurodegenerative diseases. The composition provided by the embodiments of the present application can reduce the expression level of AGER, and thus can be used for anti-inflammation, anti-oxidative stress, anti-cell damage, etc. In addition, it can also play a therapeutic role in symptoms such as diabetic complications, atherosclerosis, cancer and neurodegenerative diseases.

[0084] In some embodiments, a decrease in the expression of the DDOST gene may be beneficial to the occurrence of glycosylation. The composition provided by the embodiments of the present application can synergistically increase the expression level of the DDOST gene through the synergistic effect of rubusoside, glucosyl hesperidin and edelweiss extract, thereby achieving an anti-glycosylation effect.

[0085] In some embodiments, the edelweiss extract is prepared according to the preparation method shown in the following steps S101 to S103:

[0086] Step S101: Dry and crush the edelweiss to obtain an edelweiss crush.

[0087] Step S102: Mix the edelweiss crush with an ethanol aqueous solution to obtain a mixed solution.

[0088] Step S103: After reflux extraction and filtration of the mixed solution, concentrate the filtrate under reduced pressure to obtain an edelweiss extract.

[0089] In some embodiments, step S101 includes S1011:

[0090] S1011: Dry and crush the edelweiss by blowing air, and pass through a 40-60 mesh sieve to obtain an edelweiss crush.

[0091] In certain embodiments, the mesh number of the mesh sieve in S1011 is 50 mesh.

[0092] In some embodiments, in step S102, the mass concentration of ethanol in the ethanol aqueous solution (that is, the mass ratio of ethanol to the ethanol aqueous solution) is 60-80%, optionally 70%.

[0093] In some embodiments, in step S102, the mass-volume ratio of the edelweiss crush to the ethanol aqueous solution is 1:(2-4) g / ml; optionally 1:3 g / ml; it should be noted that the mass-volume ratio refers to the mass of the edelweiss crush to the volume of the ethanol aqueous solution.

[0094] In some embodiments, step S202 specifically includes step S1021:

[0095] S1021. Mix the edelweiss powder with an aqueous ethanol solution with a mass concentration of 70% to obtain a mixed solution, wherein the mass-volume ratio of the edelweiss powder to the aqueous ethanol solution in the mixed solution is 1:3 g / ml. Regarding the mass-volume ratio, it should be noted that for every 1 g of edelweiss powder, it corresponds to 3 ml of aqueous ethanol solution.

[0096] In some embodiments, the temperature for reflux extraction in step S103 is 80 - 90 °C, optionally 85 °C.

[0097] In some embodiments, the time for reflux extraction in step S103 is 40 - 60 minutes (min), optionally 50 minutes.

[0098] In some embodiments, the mesh number of the filter cloth for filtration after reflux extraction in step S103 is 500 - 700 mesh, optionally 600 mesh.

[0099] In some embodiments, step S103 specifically includes step S1031:

[0100] Step S1031. Reflux extract the mixed solution at a temperature of 85 °C for 50 minutes, filter it using a 600-mesh filter cloth to obtain a filtrate, and concentrate the filtrate under reduced pressure to obtain an edelweiss extract.

[0101] In some embodiments, the vacuum degree for concentration under reduced pressure in step S103 is 60 - 80 Pa, optionally 70 Pa.

[0102] In some embodiments, the temperature for concentration under reduced pressure in step S103 is 40 - 50 °C, optionally 45 °C.

[0103] In some embodiments, the time for concentration under reduced pressure in step S103 is 2 - 8 hours, optionally 3 hours.

[0104] In some embodiments, in step S103, the filtrate is concentrated under reduced pressure to obtain a solid, i.e., an edelweiss extract.

[0105] In some embodiments, the mass ratio of rubusoside, glucosyl hesperidin, and edelweiss extract is (250 - 350):(50 - 100):(0.75 - 15). This is beneficial for exerting the synergistic effect of rubusoside, glucosyl hesperidin, and edelweiss extract.

[0106] In some embodiments, the mass ratio of rubusoside, glucosyl hesperidin, and edelweiss extract is 350:100:15. This is beneficial for exerting the synergistic effect of rubusoside, glucosyl hesperidin, and edelweiss extract.

[0107] In some embodiments, the mass ratio of raspberry ketone, glucosyl hesperidin and edelweiss extract is 250:50:0.75. This is conducive to exerting the synergistic effect of raspberry ketone, glucosyl hesperidin and edelweiss extract.

[0108] In some embodiments, in the composition, the concentration of raspberry ketone is 250 - 350 micrograms per milliliter, the concentration of glucosyl hesperidin is 50 - 100 micrograms per milliliter, and the concentration of edelweiss extract is 0.75 - 15 micrograms per milliliter. This is conducive to exerting the synergistic effect of raspberry ketone, glucosyl hesperidin and edelweiss extract.

[0109] In some embodiments, in the composition, the concentration of raspberry ketone is 250 micrograms per milliliter, the concentration of glucosyl hesperidin is 50 micrograms per milliliter, and the concentration of edelweiss extract is 0.75 micrograms per milliliter. This is conducive to exerting the synergistic effect of raspberry ketone, glucosyl hesperidin and edelweiss extract.

[0110] In some embodiments, in the composition, the concentration of raspberry ketone is 350 micrograms per milliliter, the concentration of glucosyl hesperidin is 100 micrograms per milliliter, and the concentration of edelweiss extract is 15 micrograms per milliliter. This is conducive to exerting the synergistic effect of raspberry ketone, glucosyl hesperidin and edelweiss extract.

[0111] In some embodiments, the composition further includes a solvent for dissolving raspberry ketone, glucosyl hesperidin and edelweiss extract, so that the composition forms a solution.

[0112] <Skin care product>

[0113] It is easy to understand that the composition described in the first aspect can be used for skin care. Accordingly, the embodiments of the present application also provide a skin care product. The skin care product is a composition for skin care. The skin care product includes the composition described in the first aspect.

[0114] In some embodiments, the skin care product is the composition described in the first aspect.

[0115] In some embodiments, the skin care product is an external skin preparation.

[0116] In some embodiments, the skin care product is an external skin preparation, and the skin care product further includes a carrier.

[0117] Optionally, the skin care product may include carriers in various forms, such as solutions, aqueous solutions, oils, double-layer water-oil mixtures, multi-layer water-oil mixtures, emulsions, serums, toners, lotion toners, milky emulsions, gels, pastes, creams, pastes, suspensions, sprays, solids, facial cleansers, foam cleansers, face creams, gels, emulsions, muds, eye creams, freckle-removing serums, anti-aging serums, sunscreens, liquid foundations, BB creams, eyebrow pencils, eyebrow powders, blushes, contour powders, contour compacts, highlighter sticks, highlighter powders, lipsticks, lip glosses, lip liners, lip balms / lip moisturizers, etc.

[0118] <Use>

[0119] In some embodiments, the embodiments of the present application provide a use of raspberry ketone, glucosyl hesperidin and edelweiss extract in the preparation of a skin care product. The combined use of raspberry ketone, glucosyl hesperidin and edelweiss extract can increase the expression level of DDOST in skin cells, reduce the expression level of AGER in skin cells, and reduce the expression level of CD-36 in skin cells. Therefore, the skin care product can achieve the effects of increasing the expression level of DDOST in skin cells, reducing the expression level of AGER in skin cells, and reducing the expression level of CD-36 in skin cells.

[0120] In some embodiments, the embodiments of the present application also provide a use of raspberry ketone, glucosyl hesperidin and edelweiss extract in the preparation of a DDOST expression promoter. The DDOST expression promoter can be used to increase the expression level of DDOST in skin cells.

[0121] In some embodiments, the embodiments of the present application also provide a use of raspberry ketone, glucosyl hesperidin and edelweiss extract in the preparation of an AGER expression inhibitor. The AGER expression inhibitor can be used to reduce the expression level of AGER in skin cells.

[0122] In some embodiments, the embodiments of the present application also provide a use of raspberry ketone, glucosyl hesperidin and edelweiss extract in the preparation of a CD-36 expression inhibitor. The CD-36 expression inhibitor can be used to reduce the expression level of CD-36 in skin cells.

[0123] In some embodiments, the embodiments of the present application also provide a use of raspberry ketone, glucosyl hesperidin and edelweiss extract in the preparation of an anti-aging preparation.

[0124] In some embodiments, the embodiments of the present application also provide a use of raspberry ketone, glucosyl hesperidin and edelweiss extract in the preparation of an anti-glycation preparation.

[0125] In some embodiments, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of a DDOST expression promoter. The DDOST expression promoter can be used to increase the DDOST expression level in skin cells.

[0126] In some embodiments, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of an AGER expression inhibitor. The AGER expression inhibitor can be used to reduce the AGER expression level in skin cells.

[0127] In some embodiments, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of a CD-36 expression inhibitor. The CD-36 expression inhibitor can be used to reduce the CD-36 expression level in skin cells.

[0128] In some embodiments, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of an anti-aging preparation.

[0129] In some embodiments, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of an anti-glycation preparation.

[0130] In some embodiments, the embodiments of the present application further provide the use of the glucosyl hesperidin-containing composition described in the first aspect in the preparation of a skin care product.

[0131] In some embodiments, the composition is used for anti-aging, thereby improving the anti-aging effect of the skin care product.

[0132] In some embodiments, the composition is used for anti-glycation, thereby improving the anti-glycation effect of the skin care product. AGEs, inflammation and oxidative stress activated by binding to the AGER protein may further promote the glycation reaction. The composition of the embodiments of the present application can regulate the AGER gene upstream of glycation and inhibit the production of AGER protein through the action of rubusoside, glucosyl hesperidin and edelweiss extract, and thus can be used to inhibit further glycation reactions and achieve an anti-glycation effect.

[0133] In some embodiments, the composition is used to increase the expression level of the DDOST gene in skin cells.

[0134] In some embodiments, the composition is used to reduce the expression level of the AGER gene in skin cells.

[0135] In some embodiments, the composition is used to reduce the production of advanced glycation end product-specific receptors in skin cells. The AGER (also known as RAGE) protein is the receptor for advanced glycation end products. The composition of the embodiments of the present application can inhibit the production of the AGER protein through the actions of rubusoside, glucosyl hesperidin, and edelweiss extract, and thus can be used to reduce the production of advanced glycation end product-specific receptors in skin cells.

[0136] In some embodiments, the composition is used to reduce the production of advanced glycation end products (AGEs) in skin cells. AGEs, through the activation of inflammation and oxidative stress by binding to the AGER protein, may further promote the glycosylation reaction. The composition of the embodiments of the present application can regulate the AGER gene upstream of glycosylation and inhibit the production of the AGER protein through the actions of rubusoside, glucosyl hesperidin, and edelweiss extract, and thus can be used to inhibit further glycosylation reactions and indirectly reduce the accumulation of this positive feedback-driven AGEs.

[0137] In some embodiments, the composition is used to reduce the production of human leukocyte differentiation antigen 36 in skin cells.

[0138] In some embodiments, the skin cells are human immortalized keratinocytes (abbreviated as HaCaT cells).

[0139] <Preparation Example>

[0140] Prepare the edelweiss extract according to the preparation method shown in the following steps S201 to S203:

[0141] Step S201: Blow-dry and crush edelweiss, and pass through a 50-mesh sieve to obtain edelweiss powder;

[0142] Step S202: Mix the edelweiss powder with an aqueous ethanol solution with a mass concentration of 70% to obtain a mixed solution, wherein the mass-to-volume ratio of the edelweiss powder to the aqueous ethanol solution in the mixed solution is 1:3 g / ml; regarding the mass-to-volume ratio, it should be noted that every 1 g of edelweiss powder corresponds to 3 ml of aqueous ethanol solution;

[0143] Step S203: Reflux and extract the mixed solution at a temperature of 85°C for 50 minutes, filter with a 600-mesh filter cloth to obtain a filtrate, and concentrate the filtrate under reduced pressure to obtain an edelweiss extract; wherein, the vacuum degree of reduced pressure concentration is 70 Pa, the temperature of reduced pressure concentration is 45°C, and the time of reduced pressure concentration is 3 hours.

[0144] <Experiment>

[0145] <Experimental Example 1, Detection of Cell Viability>

[0146] 1. Prepare the following samples:

[0147] Sample 1-1:

[0148] Sample 1-1 is the first solution, and its preparation method is as follows:

[0149] Mix phyllodulcin with a DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin to obtain the first solution; the concentration of phyllodulcin in the first solution is 500 micrograms per milliliter.

[0150] Sample 1-2:

[0151] Sample 1-2 is the second solution, and its preparation method is basically the same as that of the first solution, except that the concentration of phyllodulcin is 250 micrograms per milliliter.

[0152] Sample 1-3:

[0153] Sample 1-3 is the third solution, and its preparation method is basically the same as that of the first solution, except that the concentration of phyllodulcin is 125 micrograms per milliliter.

[0154] Sample 1-4:

[0155] Sample 1-4 is the fourth solution, and its preparation method is basically the same as that of the first solution, except that the concentration of phyllodulcin is 62.5 micrograms per milliliter.

[0156] Sample 1-5:

[0157] Sample 1-5 is the fifth solution, and its preparation method is basically the same as that of the first solution, except that the concentration of phyllodulcin is 31.25 micrograms per milliliter.

[0158] Sample 1-6:

[0159] Sample 1-6 is the sixth solution, and its preparation method is as follows:

[0160] Mix glucosyl hesperidin with a DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin to obtain the sixth solution; the concentration of glucosyl hesperidin in the sixth solution is 100 micrograms per milliliter.

[0161] Sample 1-7:

[0162] Sample 1-7 is the seventh solution, and its preparation method is basically the same as that of the sixth solution, except that the concentration of glucosyl hesperidin is 50 micrograms per milliliter.

[0163] Sample 1-8:

[0164] Sample 1-8 is the eighth solution, and its preparation method is basically the same as that of the sixth solution, except that the concentration of glucosyl hesperidin is 25 micrograms per milliliter.

[0165] Sample 1-9:

[0166] Samples 1-9 are the ninth solution, and the preparation method is basically the same as that of the sixth solution, except that the concentration of glucosyl hesperidin is 12.5 micrograms per milliliter.

[0167] Samples 1-10:

[0168] Samples 1-10 are the tenth solution, and the preparation method is basically the same as that of the sixth solution, except that the concentration of glucosyl hesperidin is 6.225 micrograms per milliliter.

[0169] Samples 1-11:

[0170] Samples 1-11 are the eleventh solution, and the preparation method is as follows:

[0171] Mix the edelweiss extract with the DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin to obtain the sixth solution; the concentration of the edelweiss extract in the sixth solution is 15 micrograms per milliliter, and the edelweiss extract is prepared according to the preparation method shown in steps S201-S203.

[0172] Samples 1-12:

[0173] Samples 1-12 are the twelfth solution, and the preparation method is basically the same as that of the eleventh solution, except that the concentration of the edelweiss extract is 7.5 micrograms per milliliter.

[0174] Samples 1-13:

[0175] Samples 1-13 are the thirteenth solution, and the preparation method is basically the same as that of the eleventh solution, except that the concentration of the edelweiss extract is 3.75 micrograms per milliliter.

[0176] Samples 1-14:

[0177] Samples 1-14 are the fourteenth solution, and the preparation method is basically the same as that of the eleventh solution, except that the concentration of the edelweiss extract is 1.875 micrograms per milliliter.

[0178] Samples 1-15:

[0179] Samples 1-15 are the fifteenth solution, and the preparation method is basically the same as that of the eleventh solution, except that the concentration of the edelweiss extract is 0.75 micrograms per milliliter.

[0180] 2. Test method

[0181] The test method includes the following steps S301 to 304:

[0182] Step S301, cell seeding.

[0183] Specifically, human immortalized keratinocytes (hereinafter referred to as HaCaT cells) were taken and seeded into a 96-well plate at an inoculation density of 2×10 4 cells / well. 100 microliters (μL) of DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin was added to each well, and then incubated in an incubator (the preset conditions of the incubator were: 5% CO2, 37°C) for 24 hours.

[0184] Step S302, drug administration treatment.

[0185] Specifically, a blank group, a control group and 15 experimental groups were set up. The 15 experimental groups were: drug administration experimental group 1, drug administration experimental group 2, drug administration experimental group 3, drug administration experimental group 4, drug administration experimental group 5, drug administration experimental group 6, drug administration experimental group 7, drug administration experimental group 8, drug administration experimental group 9, drug administration experimental group 10, drug administration experimental group 11, drug administration experimental group 12, drug administration experimental group 13, drug administration experimental group 14, drug administration experimental group 15;

[0186] When the plating rate of the cells in the 96-well plate reached 40% - 50%, 3 corresponding replicate wells (used as parallel groups) were set for each group in the control group and the 15 experimental groups, and each well contained cultured cells;

[0187] 100 microliters of DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin solution was added to the control group;

[0188] 100 microliters of the corresponding drug administration treatment was added to each experimental group respectively. Among them, the drug administration treatments corresponding to drug administration experimental group 1, drug administration experimental group 2, drug administration experimental group 3, drug administration experimental group 4, drug administration experimental group 5, drug administration experimental group 6, drug administration experimental group 7, drug administration experimental group 8, drug administration experimental group 9, drug administration experimental group 10, drug administration experimental group 11, drug administration experimental group 12, drug administration experimental group 13, drug administration experimental group 14, drug administration experimental group 15 were: sample 1-1, sample 1-2, sample 1-3, sample 1-4, sample 1-5, sample 1-6, sample 1-7, sample 1-8, sample 1-9, sample 1-10, sample 1-11, sample 1-12, sample 1-13, sample 1-14, sample 1-15;

[0189] After drug administration, the control group and the 15 experimental groups were placed in an incubator (the preset conditions of the incubator were: 5% CO2, 37°C) and cultured for 24 hours.

[0190] Step S303, CCK8 detection.

[0191] After incubating the cells in the control group and each of the 15 experimental groups for 24 hours, discard the supernatant, add 100 μL of CCK8 working solution, and incubate in the dark at 37 °C for 2 hours. After the incubation, read the corresponding OD values of each group in the control group and the 15 experimental groups at 450 nm and 650 nm. Calculate the corrected OD value according to the following formula, and use the corrected OD value as the relative viability of each group;

[0192] Corrected OD value = OD value at 450 nm - OD value at 630 nm;

[0193] Among them, the CCK8 working solution is from Super-Enhanced Cell Counting Kit-8 (Ultra-Powerful CCK-8 Kit), Beyotime.

[0194] Step S304: Calculate the cell survival rate of each experimental group.

[0195] Set the cell survival rate of the control group to 100% as the benchmark, and then determine the cell survival rate of each experimental group;

[0196] Among them, the calculation formula for the cell survival rate of each experimental group is as follows:

[0197] Cell survival rate = [(Relative viability of the experimental group - Relative viability of the blank group) / (Relative viability of the control group - Relative viability of the blank group)] × 100%;

[0198] Among them, the relative viability of the blank group is mainly used to correct the background value during the detection by the microplate reader and exclude the interference of factors such as the culture medium on the OD value. It can be determined as follows: Select a 96-well plate, set blank wells on it. The blank wells only add CCK-8 working solution and no cells; Read the OD values of the blank wells at 450 nm and 630 nm respectively, subtract the OD value at 630 nm from the OD value at 450 nm to obtain the corrected OD value of the blank group, which is used as the relative viability of the blank group.

[0199] 3. Experimental results and analysis:

[0200] The cell survival rates of each group are shown in Table 1 and Figures 1 - 3 .

[0201] Figure 1 is a schematic diagram of the cell survival rate of dosing experimental groups 1-5 and the control group; 1, 2, 3, 4, 5, C on the abscissa represent dosing experimental groups 1-5 and the control group respectively.

[0202] Figure 2 is a schematic diagram of the cell survival rate of dosing experimental groups 6-10 and the control group; 6, 7, 8, 9, 10, C on the abscissa represent dosing experimental groups 6-10 and the control group respectively.

[0203] Figure 3 It is a schematic diagram of the cell survival rate of administration experimental groups 11 - 15 and the control group; 11, 12, 13, 14, 15, and C on the abscissa respectively represent administration experimental groups 11 - 15 and the control group.

[0204] Table 1. Cell survival rate

[0205]

[0206]

[0207] According to the above results, it can be seen that after raspberry glycoside, glucosyl hesperidin, and edelweiss extract at different concentrations act on cells, they have a very high cell survival rate. Therefore, they have no adverse effects on cells.

[0208] <Experimental Example 2, Detection of mRNA Expression Level>

[0209] 1. Prepare the following samples:

[0210] Sample 2 - 1:

[0211] Sample 2 - 1 is the sixteenth solution, and the preparation method is as follows:

[0212] Mix raspberry glycoside, MGO, and a DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin to obtain the sixteenth solution; the concentration of raspberry glycoside in the sixteenth solution is 250 micrograms per milliliter, and the concentration of MGO is 500 micromoles per liter (μmol / L).

[0213] Sample 2 - 2:

[0214] Sample 2 - 2 is the seventeenth solution, and the preparation method is as follows:

[0215] Mix glucosyl hesperidin, MGO, and a DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin to obtain the seventeenth solution; the concentration of glucosyl hesperidin in the seventeenth solution is 50 micrograms per milliliter, and the concentration of MGO is 500 micromoles per liter (μmol / L).

[0216] Sample 2 - 3:

[0217] Sample 2 - 3 is the eighteenth solution, and the preparation method is as follows:

[0218] Mix edelweiss extract, MGO, and a DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin to obtain the eighteenth solution; the concentration of edelweiss extract in the eighteenth solution is 0.75 micrograms per milliliter, and the concentration of MGO is 500 micromoles per liter (μmol / L).

[0219] Sample 2-4:

[0220] Sample 2-4 is the nineteenth solution, and its preparation method is as follows:

[0221] Mix phyllodulcin, glucosyl hesperidin, edelweiss extract, MGO, and DMEM medium solution containing 10% FBS and 1% penicillin / streptomycin to obtain the nineteenth solution; in the nineteenth solution, the concentration of phyllodulcin is 250 micrograms per milliliter, the concentration of glucosyl hesperidin is 50 micrograms per milliliter, the concentration of edelweiss extract is 0.75 micrograms per milliliter, the concentration of MGO is 500 micromoles per liter (μmol / L), and the edelweiss extract is prepared according to the preparation method shown in steps S201 - S203.

[0222] Sample 2-5:

[0223] Sample 2-5 is the twentieth solution, and its preparation method is basically the same as that of the sixteenth solution, except that the concentration of phyllodulcin is 350 micrograms per milliliter.

[0224] Sample 2-6:

[0225] Sample 2-6 is the twenty-first solution, and its preparation method is basically the same as that of the seventeenth solution, except that the concentration of glucosyl hesperidin is 100 micrograms per milliliter.

[0226] Sample 2-7:

[0227] Sample 2-7 is the twenty-second solution, and its preparation method is basically the same as that of the eighteenth solution, except that the concentration of edelweiss extract is 15 micrograms per milliliter.

[0228] Sample 2-8:

[0229] Sample 2-8 is the twenty-third solution, and its preparation method is basically the same as that of the nineteenth solution, except that the concentration of phyllodulcin is 350 micrograms per milliliter, the concentration of glucosyl hesperidin is 100 micrograms per milliliter, and the concentration of edelweiss extract is 15 micrograms per milliliter.

[0230] 2. Experimental method

[0231] The experimental method includes the following steps S401 - S406:

[0232] S401. Cell seeding.

[0233] Seed HaCaT cells into the culture wells of a six-well plate at an inoculation density of 80×10 4 cells / well, and then add 2 milliliters of medium solution to each well. Incubate in an incubator at 37 degrees Celsius and 5% CO2 for 24 hours to obtain a six-well plate containing cells to be treated.

[0234] Among them, the culture medium solution is a DMEM culture medium solution containing 10% FBS and 1% penicillin / streptomycin solution.

[0235] S402. Cell treatment and drug administration.

[0236] A blank control group (i.e., the Control group), a control experimental group (i.e., the MGO group), and 8 drug administration experimental groups are set up. The 8 drug administration experimental groups are respectively: the sample 2-1 experimental group, the sample 2-2 experimental group, the sample 2-3 experimental group, the sample 2-4 experimental group, the sample 2-5 experimental group, the sample 2-6 experimental group, the sample 2-7 experimental group, and the sample 2-8 experimental group;

[0237] Six-well plates containing the cells to be treated are configured for each group; among them, on the six-well plates corresponding to each experimental group such as the control experimental group and the 8 drug administration experimental groups, 3 replicate wells (used as 3 parallel groups, i.e., parallel groups 1 to 3) are set for each experimental group, and each well contains the cells to be treated for subsequent processing; on the six-well plate corresponding to the blank control group, a well containing the cells to be treated is set for the blank control group for subsequent processing;

[0238] For the 8 drug administration experimental groups, 2 ml of the drug administration treatment agent is added to each parallel group of each drug administration experimental group for drug administration treatment. Among them, the drug administration treatment agents corresponding to the sample 2-1 experimental group, the sample 2-2 experimental group, the sample 2-3 experimental group, the sample 2-4 experimental group, the sample 2-5 experimental group, the sample 2-6 experimental group, the sample 2-7 experimental group, and the sample 2-8 experimental group are successively: sample 2-1, sample 2-2, sample 2-3, sample 2-4, sample 2-5, sample 2-6, sample 2-7, sample 2-8;

[0239] For the blank control group, 2 ml of a DMEM culture medium solution containing 10% FBS and 1% penicillin / streptomycin solution is added for control treatment;

[0240] For the MGO group, 2 ml of the MGO solution is added to each parallel group of the MGO group for control treatment;

[0241] After drug administration and control treatment, the six-well plates corresponding to each group are placed in an incubator (the preset conditions of the incubator are: 5% CO2, 37 °C) and cultured for 24 hours.

[0242] S403. Extract RNA.

[0243] Use an RNA extraction kit to extract the RNA of the cells in each group in step S102 to obtain RNA samples;

[0244] Among them, the RNA extraction kit is TransZol Up Plus RNA Kit; the RNA extraction method is carried out according to the operation method described in the instruction manual of TransZolUp Plus RNA Kit.

[0245] S404. RT-PCR processing.

[0246] Perform RT-PCR processing on the RNA samples of each group in step S103 to obtain RT-PCR samples;

[0247] Among them, the RT-PCR method is carried out according to the operation steps of Experiment 12 described in "Molecular Biology Experiment Guide (4th Edition)" (ISBN: 9787040556254).

[0248] S405. Q-PCR program.

[0249] Perform Q-PCR processing on the RT-PCR samples of each experimental group in step S104 to obtain Q-PCR samples;

[0250] Among them, the Q-PCR method is carried out according to the operation steps of Experiment 13 described in "Molecular Biology Experiment Guide (4th Edition)" (ISBN: 9787040556254).

[0251] S406. Data processing.

[0252] Use the 2-△△Ct method to analyze the mRNA expression levels of related genes in each group of HaCaT cells in combination with the Q-PCR samples. Oneway-ANOVA statistical analysis is used for the data between groups. Among them, P < 0.05 indicates significant differences and statistical significance;

[0253] The related genes mentioned above are the AGER gene, CD-36 gene, and DDOST gene.

[0254] 3. Experimental results and analysis

[0255] The experimental results are shown in Tables 2 to 4 specifically, and Figures 4 - 9 .

[0256] Figure 4 A schematic diagram showing the relative mRNA levels (Relative mRNA level of AGER) of the AGER gene in the Control group, MGO group, Sample 2-1 experimental group, Sample 2-2 experimental group, Sample 2-3 experimental group, and Sample 2-4 experimental group; Figure 4In it, C, M, 1, 2, 3, 4 on the abscissa respectively represent the Control group, MGO group, experimental group of sample 2-1, experimental group of sample 2-2, experimental group of sample 2-3, and experimental group of sample 2-4.

[0257] Figure 5 A schematic diagram showing the relative mRNA levels (Relative mRNA level of AGER) of the AGER gene in the Control group, MGO group, experimental group of sample 2-5, experimental group of sample 2-6, experimental group of sample 2-7, and experimental group of sample 2-8; Figure 5 In it, C, M, 5, 6, 7, 8 on the abscissa respectively represent the Control group, MGO group, experimental group of sample 2-5, experimental group of sample 2-6, experimental group of sample 2-7, and experimental group of sample 2-8.

[0258] Figure 6 A schematic diagram showing the relative mRNA levels (Relative mRNA level of CD-36) of the CD-36 gene in the Control group, MGO group, experimental group of sample 2-1, experimental group of sample 2-2, experimental group of sample 2-3, and experimental group of sample 2-4; Figure 6 In it, C, M, 1, 2, 3, 4 on the abscissa respectively represent the Control group, MGO group, experimental group of sample 2-1, experimental group of sample 2-2, experimental group of sample 2-3, and experimental group of sample 2-4.

[0259] Figure 7 A schematic diagram showing the relative mRNA levels (Relative mRNA level of CD-36) of the CD-36 gene in the Control group, MGO group, experimental group of sample 2-5, experimental group of sample 2-6, experimental group of sample 2-7, and experimental group of sample 2-8; Figure 7 In it, C, M, 5, 6, 7, 8 on the abscissa respectively represent the Control group, MGO group, experimental group of sample 2-5, experimental group of sample 2-6, experimental group of sample 2-7, and experimental group of sample 2-8.

[0260] Figure 8 A schematic diagram showing the relative mRNA levels (Relative mRNA level of DDOST) of the DDOST gene in the Control group, MGO group, experimental group of sample 2-1, experimental group of sample 2-2, experimental group of sample 2-3, and experimental group of sample 2-4; Figure 8 In it, C, M, 1, 2, 3, 4 on the abscissa respectively represent the Control group, MGO group, experimental group of sample 2-1, experimental group of sample 2-2, experimental group of sample 2-3, and experimental group of sample 2-4.

[0261] Figure 9 Shows a schematic diagram of the relative mRNA levels of the DDOST gene (Relative mRNA level of DDOST) in the Control group, MGO group, experimental groups of Sample 2-5, Sample 2-6, Sample 2-7, and Sample 2-8; Figure 9 Among them, C, M, 5, 6, 7, and 8 on the abscissa represent the Control group, MGO group, experimental groups of Sample 2-5, Sample 2-6, Sample 2-7, and Sample 2-8, respectively.

[0262] Table 2, mRNA expression levels of related genes in the Control group, MGO group, and experimental groups of Sample 2-1 to 2-4

[0263]

[0264]

[0265] Table 3, mRNA expression levels of related genes in the Control group, MGO group, and experimental groups of Sample 2-5 to 2-8

[0266]

[0267]

[0268] Table 4, Changes in mRNA expression levels of related genes in the drug-administered experimental groups relative to the MGO group

[0269]

[0270] According to Tables 2 to 4 and Figures 4 - 5 It can be seen that: in the drug-administered experimental groups, only the experimental groups of Sample 2-4 and Sample 2-8 can significantly reduce the expression level of AGER, even far lower than that of the blank control group. This shows that when raspberry ketone, glucosyl hesperidin, and edelweiss extract are combined, they can produce a synergistic effect, thereby achieving the effect of reducing the expression level of AGER.

[0271] According to Tables 2 to 4 and Figures 6 - 7 It can be seen that: in the drug-administered experimental groups, only the experimental groups of Sample 2-4 and Sample 2-8 can significantly reduce the expression level of CD-36, even far lower than that of the blank control group. This shows that when raspberry ketone, glucosyl hesperidin, and edelweiss extract are combined, they can produce a synergistic effect, thereby achieving the effect of reducing the expression level of CD-36.

[0272] According to Tables 2 to 4 and Figures 8 - 9It can be seen that among the experimental groups, only the experimental groups of sample 2-4 and sample 2-8 can significantly increase the expression level of DDOST, even far higher than that of the blank control group, and the other experimental groups are lower than the blank control group. This shows that when raspberry glycoside, glucosyl hesperidin and edelweiss extract are combined, they can produce a synergistic effect, thus achieving the effect of enhancing the expression level of DDOST.

[0273] The above specific implementation manners have described the present invention in detail, but these do not constitute a limitation to the present invention. The protection scope of the present invention is not limited to the above implementation manners. Any equivalent modification or change made by those of ordinary skill in the art according to the disclosure of the present invention should be included in the protection scope recorded in the claims.

Claims

1. A composition containing glucosyl hesperidin, characterized in that, Comprising: Rubusoside, glucosyl hesperidin and Leontopodium alpinum extract.

2. The composition containing glucosyl hesperidin according to claim 1, wherein The mass ratio of rubusoside, glucosyl hesperidin and Leontopodium alpinum extract is (250 - 350):(50 - 100):(0.75 - 15).

3. The composition containing glucosyl hesperidin according to claim 1, characterized in that, The composition is a skin care product.

4. Use of the composition containing glucosyl hesperidin according to claim 1 in the preparation of a skin care product.

5. The use according to claim 4, wherein, Rubusoside, glucosyl hesperidin and Leontopodium alpinum extract are used to synergistically promote the expression of DDOST in skin cells and / or inhibit the expression of AGER in skin cells and / or inhibit the expression of CD-36 in skin cells.

6. Use of the composition containing glucosyl hesperidin according to any one of claims 1 - 2 in the preparation of a DDOST expression promoter, an AGER expression inhibitor or a CD-36 expression inhibitor.

7. Use of the composition containing glucosyl hesperidin according to any one of claims 1 - 2 in the preparation of an anti-aging preparation or an anti-glycation preparation.

8. Use of rubusoside, glucosyl hesperidin and Leontopodium alpinum extract in the preparation of an anti-aging preparation, an anti-glycation preparation, a DDOST expression promoter, an AGER expression inhibitor or a CD-36 expression inhibitor.

9. Use of rubusoside, glucosyl hesperidin and Leontopodium alpinum extract in the preparation of a skin care product.

10. According to the use of claim 9, the mass ratio of rubusoside, glucosyl hesperidin and Leontopodium alpinum extract is (250 - 350):(50 - 100):(0.75 - 15).

Images